Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European …
Moderate aLimited use in the US/Europe. bNot licensed in the US cPrescribing highly
restricted in the US; withdrawn in Europe. dNot licensed in Europe. eTo be available as a …
restricted in the US; withdrawn in Europe. dNot licensed in Europe. eTo be available as a …
Metabolic syndrome and insulin resistance: perioperative considerations.
HS Bagry, S Raghavendran, F Carli - Anesthesiology, 2008 - europepmc.org
Metabolic syndrome represents a constellation of risk factors associated with increased
incidence of cardiovascular disease and progression to diabetes mellitus. Insulin resistance …
incidence of cardiovascular disease and progression to diabetes mellitus. Insulin resistance …
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European …
Glycaemic management in type 2 diabetes mellitus has become increasingly complex and,
to some extent, controversial, with a widening array of pharmacological agents now …
to some extent, controversial, with a widening array of pharmacological agents now …
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Background Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but
its effect on cardiovascular morbidity and mortality has not been determined. Methods We …
its effect on cardiovascular morbidity and mortality has not been determined. Methods We …
Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease
OBJECTIVE The two major classes of antidiabetic drugs, sulfonylureas and metformin, may
differentially affect macrovascular complications and mortality in diabetic patients. We …
differentially affect macrovascular complications and mortality in diabetic patients. We …
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
ORIGIN Trial Investigators Mellbin Linda G … - European heart …, 2013 - academic.oup.com
Aims Hypoglycaemia caused by glucose-lowering therapy has been linked to
cardiovascular (CV) events. The ORIGIN trial provides an opportunity to further assess this …
cardiovascular (CV) events. The ORIGIN trial provides an opportunity to further assess this …
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus
ContextPeroxisome proliferator–activated receptors (PPARs) are nuclear transcription
factors that modulate gene expression. Therapeutic agents targeting 2 distinct families of …
factors that modulate gene expression. Therapeutic agents targeting 2 distinct families of …
Dose–response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study
Background: Over the past 30 years, the relation between use of sulfonylureas to treat type 2
diabetes and the risk of cardiovascular events has been vigorously debated. The purpose of …
diabetes and the risk of cardiovascular events has been vigorously debated. The purpose of …
The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial
Aims To explore the impact of glucose lowering treatment on prognosis in diabetic patients
with myocardial infarction. Methods and results 1181 type 2 diabetic patients (mean age 68 …
with myocardial infarction. Methods and results 1181 type 2 diabetic patients (mean age 68 …
Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events
OBJECTIVE Sulfonylureas have been associated with an increased risk of cardiovascular
adverse events and hypoglycemia, but it is unclear if these risks vary with different agents …
adverse events and hypoglycemia, but it is unclear if these risks vary with different agents …